Scholarlink

Purpose <p>Nontuberculous mycobacterial pulmonary disease (NTM-PD) presents growing challenges due to rising prevalence, antimicrobial resistance, and poor treatment outcomes. Omadacycline shows potential as a treatment option given its broad-spectrum activity, oral bioavailability, and high pulmonary penetration, yet optimal dosing remains unclear. This study aimed to develop a permeability-limited multi-compartment lung physiologically based pharmacokinetic (PBPK) model of omadacycline to predict epithelial lining fluid (ELF) concentrations and support pharmacokinetic/pharmacodynamic (PK/PD)-based dose optimization for NTM-PD.</p> Methods <p>A whole-body PBPK model was developed using Simcyp<sup>®</sup> v24 and validated against 25 clinical pharmacokinetic studies. The model was then extended to incorporate detailed pulmonary compartments and transporter-mediated efflux, and simulated ELF concentrations were verified using clinical bronchoalveolar lavage data. Monte Carlo simulations were conducted to estimate ELF exposures and probability of target attainment (PTA) for three oral omadacycline regimens (300, 450, and 600&#xa0;mg QD).</p> Results <p>PK/PD target attainment analysis showed that a 300&#xa0;mg once-daily oral dose of omadacycline is sufficient to achieve target attainment for pathogens with MICs ≤ 0.5&#xa0;mg/L, corresponding to MIC<sub>90</sub> values. The cumulative fraction of response (CFR) was lower in cystic fibrosis (CF)-derived isolates than in non-CF isolates.</p> Conclusion <p>These results support the efficacy of 300&#xa0;mg omadacycline against the majority of strains (93% of isolates) and demonstrate the utility of PBPK modeling in optimizing omadacycline regimens for NTM-PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dose optimization of omadacycline for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) using a physiologically based pharmacokinetic modeling approach

  • 期刊论文

  • 发表日期：

    2025年10月13日

查看全文
  • Dong-Gyu Heo,
  • Madeline Sanders,
  • Vinicius Calado Nogueira de Moura,
  • Charles L. Daley,
  • Paul M. Beringer,
  • Eunjin Hong

摘要

Purpose

Nontuberculous mycobacterial pulmonary disease (NTM-PD) presents growing challenges due to rising prevalence, antimicrobial resistance, and poor treatment outcomes. Omadacycline shows potential as a treatment option given its broad-spectrum activity, oral bioavailability, and high pulmonary penetration, yet optimal dosing remains unclear. This study aimed to develop a permeability-limited multi-compartment lung physiologically based pharmacokinetic (PBPK) model of omadacycline to predict epithelial lining fluid (ELF) concentrations and support pharmacokinetic/pharmacodynamic (PK/PD)-based dose optimization for NTM-PD.

Methods

A whole-body PBPK model was developed using Simcyp® v24 and validated against 25 clinical pharmacokinetic studies. The model was then extended to incorporate detailed pulmonary compartments and transporter-mediated efflux, and simulated ELF concentrations were verified using clinical bronchoalveolar lavage data. Monte Carlo simulations were conducted to estimate ELF exposures and probability of target attainment (PTA) for three oral omadacycline regimens (300, 450, and 600 mg QD).

Results

PK/PD target attainment analysis showed that a 300 mg once-daily oral dose of omadacycline is sufficient to achieve target attainment for pathogens with MICs ≤ 0.5 mg/L, corresponding to MIC90 values. The cumulative fraction of response (CFR) was lower in cystic fibrosis (CF)-derived isolates than in non-CF isolates.

Conclusion

These results support the efficacy of 300 mg omadacycline against the majority of strains (93% of isolates) and demonstrate the utility of PBPK modeling in optimizing omadacycline regimens for NTM-PD.